Real-world evidence of fremanezumab for treating migraine in Japan: a retrospective study.

ABSTRACT:

Background

There have been very few real-world studies reported in the literature solely focusing on fremanezumab in Asia. This study aimed to evaluate the efficacy and safety of fremanezumab in a real-world setting in Japan.

Method

This single-centered, observational, retrospective study examined patients with migraines who received four doses of fremanezumab between December 2021 and August 2022 at Keio University Hospital. We assessed the changes in monthly migraine days, responder rates, and migraine-associated symptoms, as well as injection site reactions and adverse events.

Result

Twenty-nine patients were enrolled, wherein 79.3% were women. Compared with those at baseline, the monthly migraine days decreased by 5.9 days at 4 months. The 50% responder rate was 5

SUBMITTER: Ohtani S 

PROVIDER: S-EPMC10644569 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature